Completed PHASE4 INTERVENTIONAL 2-arm NCT02761174

Topical Brimonidine to Reduce Inflammation After IPL-treatment in Patients With Facial Telangiectasias

Topical Brimonidine Reduces IPL-induced Erythema Without Affecting Efficacy: a Randomized Controlled Trial in Patients With Facial Telangiectasias

Sponsor: Ellipse A/S Agern Allé 11, 2970 Hørsholm

Conditions Telangiectasias

Interventions Brimonidine IPL+air-cooling

Updated 6 times since 2017 Last updated: Jan 3, 2018 Started: Mar 13, 2016 Primary completion: Jul 11, 2016 Completion: Jan 13, 2017

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A PHASE4 clinical study on Telangiectasias, this trial is completed. The trial is conducted by Ellipse A/S Agern Allé 11, 2970 Hørsholm and has accumulated 6 data snapshots since 2016. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.

Status Flow

Change History

6 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE4
Jul 2024 — Sep 2024 [monthly]

Completed PHASE4
Jan 2021 — Jul 2024 [monthly]

Completed PHASE4
Jun 2018 — Jan 2021 [monthly]

Completed PHASE4
Jan 2018 — Jun 2018 [monthly]

Completed PHASE4

Status: Recruiting → Completed

▶ Show 1 earlier version

Jan 2017 — Jan 2018 [monthly]

Recruiting PHASE4

First recorded

Mar 2016

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Ellipse A/S Agern Allé 11, 2970 Hørsholm
Merete Haedersdal
Skinperium, Christine Dierickx

Data source: Bispebjerg Hospital

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Copenhagen NV, Denmark